Dublin, June 26, 2018 (GLOBE NEWSWIRE) -- The "Antibiotic Resistance Markets - Therapeutics By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization. 2018 to 2023" report has been added to ResearchAndMarkets.com's offering.
Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 key opportunities in this space and developed market forecasts.
We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play.
This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.
The Market Opportunity of AMR
The Key Market Opportunities in AMR
- Streptococcus Pneumoniae (DRSP)
- Campylobacter (DRC)
- Clostridium Difficile (CD)
- Staphylococcus aureus (MRSA)
- Neisseria gonorrhoeae (DRNG)
- Salmonella (DRNTS)
Therapeutic Technology Development Opportunities
- Using Viruses Against Bacteria
- Hydrolytic Enzymes Join the Fight
- Antibodies
- Vaccines
- Probiotic Technology
- Peptides vs. Pathogens
- Mining Obsolete Science
- CRISPR Antibiotics
Key Topics Covered
1. Introduction and Market Definition 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance 1.2 Defining the Opportunity 1.2.1 Revenue Market Size 1.3 Methods and Sources 1.3.1 Authors 1.3.2 Sources 1.4 U.S. Antibiotic Markets - Perspective 1.4.1 U.S. Outpatient Use of Antibiotics 1.4.2 U.S. Pharmaceutical Spending 2. Overview of a Dynamic Market 2.1 Market Players - Roles & Impacts 2.1.1 Drug manufacturers - Larger/pharmaceutical 2.1.2 Drug manufacturers - Generic 2.1.3 Contract Research and Manufacturing 2.1.4 In Vitro Diagnostics Industry 2.1.5 Drug Marketing Companies 2.1.6 Biotechnology Companies 2.1.7 Regulatory Bodies 2.2 Understanding Antimicrobial Resistance 2.2.1 What is Antimicrobial Resistance (AMR) 2.2.2 Bacteria and Other Microbes 2.2.3 The History of Antibiotics 2.2.4 The Role of Animal Husbandry 2.2.5 The Implications of Horizontal Transfer 2.2.6 The Threat of AMR 2.3 The Changing Road to New Antibiotics & Technologies 2.4 The Key Role of Diagnostics in AMR 3. The Market Opportunity of AMR 3.1 The Key Large Market Opportunities in AMR 3.1.1 Streptococcus Pneumoniae (DRSP) 3.1.2 Campylobacter (DRC) 3.1.3 Clostridium Difficile (CD) 3.1.4 Staphylococcus aureus (MRSA) 3.1.5 Neisseria gonorrhoeae (DRNG) 3.1.6 Salmonella (DRNTS) 3.2 Therapeutic Technology Development Opportunities 3.2.1 Using Viruses Against Bacteria 3.2.2 Hydrolytic Enzymes Join the Fight 3.2.3 Antibodies 3.2.4 Vaccines 3.2.5 Probiotic Technology 3.2.6 Peptides vs. Pathogens 3.2.7 Mining Obsolete Science 3.2.8 CRISPR Antibiotics 3.3. Antibiotic Resistance Recent Developments 3.3.1 Recent Developments - Importance and How to Use This Section 3.3.2 Importance of These Developments 3.3.3 How to Use This Section 3.3.72 Amicrobe, Inc., patents AMR Gel 3.3.73 Microneedle Patch to Combat Antimicrobial Resistance 3.3.74 Antimicrobial peptides find application medium 3.3.75 Antibiotic shortages fuelling antimicrobial resistance 3.3.4 Superbug Arises in China 3.3.5 Bruker Announces Acquisition of MERLIN 3.3.6 Antibiotics Firms Cempra, Melinta Therapeutics Agree to Merger 3.3.7 Antibiotic Alternative Micreos wins Most Impactful Innovation 3.3.8 Roche kicks antibiotic development into Warp Drive 3.3.9 Iterum Gains Support for Sulopenem Development 3.3.10 VenatoRx Pharmaceuticals Raises $42 Million Series B 3.3.11 Wockhardt Receives Approval for Phase III Trial 3.3.12 Phagelux, Inc. Announces Collaboration with Johnson & Johnson 3.3.13 bioMrieux, Inc. and McKesson Medical-Surgical Announce Distribution Alliance 3.3.14 AstraZeneca to sell antibiotics branch to Pfizer 3.3.15 Microbiotix and AMR Centre Announce Co-Development Agreement 3.3.16 Hennepin Life Sciences Presents Pre-Clinical Data 3.3.17 bioMrieux receives FDA clearance for expanded pathogen identification capability 3.18 Sequoia Sciences Receives FDA Fast Track Designation 3.19 Forge Therapeutics Presents New Efficacy Data 3.20 Acquisition Strategy Fills Out Roche's Pipeline 3.21 Alopexx completes trial of broad-spectrum anti-microbial vaccine 3.22 Integrated Biotherapeutics Partners with CARB-X for MRSA Vaccine 3.23 BD Molecular Test for Infectious Diarrhea Cleared 3.24 Fusion Genomics Developing All Pathogens Diagnostic 4. Key Biotechnology Companies and Their Technology 4.2 Therapeutics 4.2.1 The Medicines Company 4.2.2 Melinta Therapeutics 4.2.3 Arsanis 4.2.4 Phage Technologies S.A 4.2.5 Westway Health 4.2.6 Tetraphase Pharmaceuticals 4.2.7 BioVersys GmbH 4.2.8 Nabriva Therapeutics 4.2.9 Macrolide Pharmaceuticals 4.2.10 Nemesis Bioscience 4.2.11 C3J Therapeutics, Inc. 4.2.12 EpiBiome 4.2.13 discuva 4.2.14 SmartPhage 4.2.15 AmpliPhi Biosciences 4.2.16 Pherecydes Pharma 4.2.17 Micreos 4.2.18 Procarta Biosystems 4.2.19 Lumavita 4.2.20 Madam Therapeutics 4.2.21 Priaxon 4.2.22 Biolytx Pharmaceuticals 4.2.23 AntibioTx 4.2.24 Xellia Pharmaceuticals 4.2.25 Paratek Pharmaceuticals 4.2.26 Synereca Pharmaceuticals 4.2.27 Allecra Therapeutics 4.2.28 Fixed Phage 4.2.29 Enanta Pharmaceuticals, Inc. 4.2.30 Demuris 4.2.31 Prommune 4.2.32 Biosergen 4.2.33 Innovation Pharmaceuticals 4.2.34 Aviragen Therapeutics 4.2.35 Achillion Pharmaceuticals 4.2.36 ImmunNovative Developments, S.L. 4.2.37 Achaogen, Inc. 4.2.38 SelectX Pharmaceuticals, Inc. 4.2.39 TaiGen Biotechnology Co., Ltd. 4.2.40 Theravance Biopharma 4.2.41 Abbvie 4.2.42 KYORIN Pharmaceutical Co.,Ltd. 4.2.43 Iterum Therapeutics Limited 4.2.44 Forge Therapeutics 4.2.45 Alopexx Vaccine LLC 4.2.46 Integrated Biotherapeutics 4.2.47 Hennepin Life Sciences 4.2.48 Fedora Pharmaceuticals Inc. 4.2.49 Contrafect Corporation 4.2.50 Basilea Pharmaceutica Ltd. 4.2.51 AiCuris 4.2.52 RedHill Biopharma 4.2.53 Redx Pharma Plc/Redx Anti Infectives Ltd. 4.2.54 ABAC Therapeutics 4.2.55 Alaxia SAS 4.2.56 Antabio S.A.S 4.2.57 Auspherix Ltd 4.2.58 BioFilm Pharma 4.2.59 Centauri Therapeutics Ltd 4.2.60 Combioxin SA 4.2.61 Da Volterra 4.2.62 Debiopharm International SA 4.2.63 Deinobiotics/Deinove 4.2.64 Destiny Pharma plc 4.2.65 Eligo Bioscience 4.2.66 Helperby Therapeutics Ltd 4.2.67 Karveel Pharmaceuticals 4.2.68 MaaT Pharma 4.2.69 Motif BioSciences Inc./Motif Bio PLC 4.2.70 Mutabilis SAS 4.2.71 Neem Biotech Ltd 4.2.72 Northern Antibiotics Oy (Ltd) 4.2.73 Nosopharm 4.2.74 NovaBiotics Ltd 4.2.75 Phico Therapeutics Ltd 4.2.76 Polyphor Ltd 4.2.77 QureTech Bio AB 4.2.78 SetLance srl 4.2.79 Ultupharma AB 4.2.80 Vaxdyn 4.2.81 Vibiosphen 4.2.82 Bioaster 4.2.83 Vivexia 4.2.85 KBP Biosciences 4.2.86 Absynth Biologics 4.2.87 Spero Therapeutics 4.2.88 Merck 4.2.89 Symphogen 4.2.90 Warp Drive Bio 4.2.91 Johnson & Johnson (Janssen) 4.2.92 Pfizer 4.2.93 Allergan 4.2.95 Novartis 4.2.97 AstraZeneca 4.2.100 Cipla 4.2.101 DSM Sinochem Pharmaceuticals 4.2.102 Wockhardt Ltd. 4.2.103 VenatoRx Pharmaceuticals 4.2.104 MicuRx 4.2.105 Entasis Therapeutics 4.2.106 Merlion Pharmaceuticals 4.3 The Therapeutics Race - Summary of Companies Research Areas 5. Country Market Sizes - North America 2017 to 2023 5.1 United States of America 2017 to 2023 5.1.1 USA by Pathogen 5.1.2 USA by Technology Opportunity 5.2 Canada 2017 to 2023 5.1.1 Canada by Pathogen 5.1.2 Canada by Technology Opportunity 6. Country Markets - Europe 2017 to 2023 6.1 France 2017 to 2023 6.1.1 France by Pathogen 6.1.2 France by Technology Opportunity 6.2 Germany 2017 to 2023 6.2.1 Germany by Pathogen 6.2.2 Germany by Technology Opportunity 6.3 United Kingdom 2017 to 2023 6.3.1 United Kingdom by Pathogen 6.3.2 United Kingdom by Technology Opportunity 6.4 Spain 2017 to 2023 6.4.1 Spain by Pathogen 6.4.2 Spain by Technology Opportunity 6.5 Italy 2017 to 2023 6.5.1 Italy by Pathogen 6.5.2 Italy by Technology Opportunity 6.6 Russia 2017 to 2023 6.6.1 Russia by Pathogen 6.6.2 Russia by Technology Opportunity 6.7 Remainder of Europe and Former USSR 2017 to 2023 6.7.1 Remainder of Europe and Former USSR by Pathogen 6.7.2 Remainder of Europe and Former USSR by Technology Opportunity 7. Country Markets - Asia Pacific 2017 to 2023 7.1 China 2017 to 2023 7.1.1 China by Pathogen 7.1.2 China by Technology Opportunity 7.2 Japan 2017 to 2023 7.2.1 Japan by Pathogen 7.2.2 Japan by Technology Opportunity 7.3 South Korea 2017 to 2023 7.3.1 South Korea by Pathogen 7.3.2 South Korea by Technology Opportunity 7.4 India 2017 to 2023 7.4.1 India by Pathogen 7.4.2 India by Technology Opportunity 7.5 Australia 2017 to 2023 7.5.1 Australia by Pathogen 7.5.2 Australia by Technology Opportunity 7.6 Remainder of Asia Pacific 2017 to 2023 7.6.1 Remainder of Asia Pacific by Pathogen 7.6.2 Remainder of Asia Pacific by Technology Opportunity 8. Country Markets - Latin America, Africa & The Middle East 2017 to 2023 8.1 Brazil 2017 to 2023 8.1.1 Brazil by Pathogen 8.1.2 Brazil by Technology Opportunity 8.2 Mexico 2017 to 2023 8.2.1 Mexico by Pathogen 8.2.2 Mexico by Technology Opportunity 8.3 Remainder of Latin America 2017 to 2023 8.3.1 Remainder of Latin America by Pathogen 8.3.2 Remainder of Latin America by Technology Opportunity 8.4 Africa & The Middle East 2017 to 2023 8.4.1 Africa & The Middle East by Pathogen 8.4.2 Africa & The Middle East by Technology Opportunity 9. Global Market Summary 2017 to 2023 9.1 Global Market Summary 2017 to 2023 9.1.1 Global Market Summary by Pathogen 9.1.2 Global Market Summary by Technology Opportunity 10. The Future of AMR
Appendices I. United States Medicare System: Top Selling Drugs 2011-2015
For more information about this report visit https://www.researchandmarkets.com/research/j...iotic?w=12
CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Antibiotics
